Capnia, a private company developing novel therapeutic products using its proprietary medical gas delivery system, announces the hiring of Scott Borland as Vice President of Engineering.
Los Gatos, CA (PRWEB) September 23, 2004, : Scott Borland has joined Capnia's executive management team as Vice President of Engineering. Mr. Borland is responsible for directing the company's drug delivery development as well as device engineering and manufacturing.
Scott brings more than ten years of technology development, product development, and process engineering experience to Capnia. Most recently, he held the position of Senior Director, Engineering and Operations at Aerogen, Inc., where he was responsible for design engineering and manufacturing of core technology components and products for aerosol-based pulmonary drug delivery products. In addition, he was instrumental in regulatory activities and manufacturing scale-up of both clinical and commercially marketed products. Scott has held several positions in the medical device, drug delivery, and computer hardware industries with Therics, Inc., Topaz Technologies, and Applied Magnetics and was a Visiting Scientist at the Massachusetts Institute of Technology.
Scott holds an M.S. in Chemical Engineering from the Massachusetts Institute of Technology and a B.S. in Materials Science and Engineering from the University of Arizona.
"Scott combines a broad set of skills critical to the development and launch of the Capnia delivery platform," said Mark Platshon, CEO. "He joins us as our Phase IIb clinical trials are beginning and will have a significant impact on the design of Capnia's first commercial product. Scott will also play a key role in our other product research and development plans as well as our patent strategy."
About CAPNIA
CAPNIA is a private company developing novel therapeutic products using its proprietary medical gas delivery system. We are targeting a number of chronic diseases treatable with topical application of well understood, safe and effective gas compounds. Our first product is entering Phase IIb clinical trials for the treatment of acute migraines and related symptoms. 28 million Americans and over 240 million people worldwide suffer from this debilitating condition.
For more information, contact Capnia:
170 Knowles Dr., Suite 210
Los Gatos, CA 95032
Tel: (408) 376-0963
Fax: (408) 376-0964
Email: info@capnia.com
# # #
|
